SCHEMBL29499673

SCHEMBL29499673

Cc1[nH]c2ccccc2c1C[C@H](N)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 3/20 0.61
GAA P10253 1/20 0.61
CASP1 P29466 1/20 0.61
CASP7 P55210 1/20 0.61
TSHR P16473 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
LMNA P02545 1/20 0.54
MPO P05164 1/20 0.54
BLM P54132 1/20 0.54
PMP22 Q01453 1/20 0.54
HIF1A Q16665 1/20 0.54
HTT P42858 2/20 0.53
POLB P06746 1/20 0.51
CYP3A4 P08684 1/20 0.50
EGFR P00533 2/20 0.49
SRC P12931 1/20 0.49
SCN9A Q15858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29557291 1.00 MAPT (0.61) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL4586167 1.00 MAPT (0.61) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL195997 1.00 MAPT (0.61) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL29527665 1.00 MAPT (0.61) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL2049320 1.00 MAPT (0.61) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL7527587 0.88 SCN9A (0.58) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL7811480 0.85 MAPT (0.54) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL27312034 0.85 MAPT (0.54) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL5925150 0.85 MAPT (0.54) MAPTKDM4EALDH1A1GAACASP1
SCHEMBL18029219 0.84 FDPS (0.47) MAPTKDM4EALDH1A1GAACASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094701-A TLR3 binding bicyclic peptide ligands 2026-05-26 CN claimed
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF ALPHA 9 ONCOLOGY INC (CA) 2026-03-19 US claimed
US-20250195702-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2025-06-19 US claimed
WO-2025054727-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2025-03-20 WO claimed
WO-2025046244-A1 TLR3 BINDING BICYCLIC PEPTIDE LIGANDS BICYCLETX LIMITED (GB) 2025-03-06 WO claimed
EP-4499663-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS Provincial Health Services Authority (CA) 2025-02-05 EP claimed
CN-119213011-A Radiolabeled compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders 省卫生服务机构 2024-12-27 CN claimed
EP-4274838-B1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LTD (GB) 2024-09-25 EP claimed
US-20240123099-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2024-04-18 US claimed
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2024-04-04 US claimed
CN-117529489-A Bicyclic peptide ligands specific for NK cells 拜斯科技术开发有限公司 2024-02-06 CN claimed
EP-4274838-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BicycleTx Limited (GB) 2023-11-15 EP claimed
WO-2023207106-A1 GLP-1/GIP RECEPTOR CO-AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF 苏州星洲生物科技有限公司 2023-11-02 WO claimed
CN-116970063-A GLP-1/GIP receptor co-agonists, pharmaceutical compositions comprising same and uses thereof 苏州星洲生物科技有限公司 2023-10-31 CN claimed
WO-2023178449-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2023-09-28 WO claimed
WO-2022148974-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2022-07-14 WO claimed
CN-122094701-A TLR3 binding bicyclic peptide ligands 2026-05-26 CN disclosed
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF ALPHA 9 ONCOLOGY INC (CA) 2026-03-19 US disclosed
CN-114375163-A Compositions with sugar-like characteristics 玉米产品开发公司 2022-04-19 CN disclosed
EP-3981784-A1 REGULATORS OF CELL DIVISION Technische Universität Dresden (DE) 2022-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS PBK, KLRK1, MICA MAPT 4099/4885KDM4E 1930/4885ALDH1A1 4552/4885
US-20240123099-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS GRPR, NPY5R, NPY2R MAPT 3932/4885KDM4E 2562/4885ALDH1A1 4687/4885
US-20250195702-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS GRPR, NPY5R, NPY2R MAPT 3958/4885KDM4E 2440/4885ALDH1A1 4652/4885
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF GRPR, GIPR, GLP1R MAPT 3741/4885KDM4E 4638/4885ALDH1A1 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.